BLAINJECTIONINJECTABLEPriority Review
Approved
Mar 2017
Lifecycle
Peak
Competitive Pressure
30/100
Clinical Trials
27
Data completeness
6/8 — Strong
Priority Review
DUPIXENT (dupilumab) by Regeneron is interleukin 4 receptor alpha antagonists [moa]. Approved for interleukin-4 receptor alpha antagonist [epc]. First approved in 2017.
Drug data last refreshed 20h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
Dupilumab (DUPIXENT) is a monoclonal antibody that blocks interleukin-4 receptor alpha, interrupting a key inflammatory pathway in type 2 immune responses. It treats five inflammatory indications: atopic dermatitis, asthma, eosinophilic esophagitis, chronic rhinosinusitis with nasal polyps, and nasal polyps. The drug is administered as a subcutaneous injection and has become a cornerstone therapy across multiple allergic and inflammatory diseases.
Peak
As a peak-stage asset from Regeneron with multi-indication presence, Dupixent commands substantial brand resources across commercial and medical affairs functions, supporting a large field and account management organization.
Mechanism of Action
Interleukin 4 Receptor alpha Antagonists
Pharmacologic Class:
Interleukin-4 Receptor alpha Antagonist
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (27)
Neoadjuvant Dupilumab and Toripalimab in MSS CRC Subjects With Resectable Liver Metastases
Started Jun 2026
24 enrolled
Metastatic Colorectal CancerLiver Metastases
A Clinical Study Comparing the Bioequivalence of IBI3027 and DUPIXENT®(Dupilumab) in Healthy Chinese Volunteers
Started Apr 2026
180 enrolled
Healthy Volunteers
A Study to Describe the Real-world Effectiveness, Safety and Patterns of Use of Dupilumab in Patients With Chronic Spontaneous Urticaria
Started Mar 2026
400 enrolled
Chronic Spontaneous Urticaria
The Impact of Dupilumab Treatment on Anxiety and Depression Symptoms in Patients With Moderate-to-Severe Atopic Dermatitis
Started Feb 2026
184 enrolled
Atopic Dermatitis
A Study to Compare the Pharmacokinetics, Pharmacodynamic, Immunogenicity, and Safety of CKD-706 With US-Dupixent®, and EU-Dupixent® in Healthy Adult Participants.
Started Feb 2026
519 enrolled
Atopic Dermatitis
Worked on DUPIXENT at Regeneron? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.